Charles River Laboratories International, Inc.
NYSE:CRLMedical - Diagnostics & Research
-$2.45 today
- Market cap
- $15.97B
- Beta
- 1.45
- P/E (TTM)
- -48.3
- EPS (TTM)
- -$3.77
Volume 0.52M
Average 0.86M
CRL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Charles River Laboratories International, Inc.NYSE: CRL
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $67.29M fell 43.7% year over year, behind the -30.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.
Context
- Depreciation & amortization amounted to 10.0% of revenue in FY2025, up 1.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -43.7% toward the trailing-twelve-month pace of -30.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 403.31M USD
- Year-over-year change
- +11.5%
- 4-year CAGR
- +11.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | 403.31M | +11.5% |
| FY2024 | 2024-12-28 | 361.74M | +15.2% |
| FY2023 | 2023-12-31 | 314.12M | +3.4% |
| FY2022 | 2022-12-31 | 303.87M | +14.4% |
| FY2021 | 2021-12-31 | 265.54M | — |
Depreciation & Amortization vs competitors
How CRL compares with its peers on the latest reported figures
- CRL's LTM Jun 2026 depreciation & amortization of $297.88M is the 2nd highest of the 4 companies compared; the peer median is $57.03M.
- Its year-over-year change of -30.8% is the lowest of 4, against a peer median of +5.9%.
- Depreciation & amortization amounts to 7.4% of revenue for CRL, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $575.54M | +50.1% | -12.4% | 7.0% | |
| LTM Jun 2026 | $297.88M | -30.8% | +9.9% | 7.4% | |
| LTM Mar 2026 | $57.03M | +5.9% | +2.5% | 13.6% | |
| LTM Sep 2026 | $27.48M | -3.6% | +8.0% | 1.0% | |
| Peer median (excluding CRL) | $57.03M | +5.9% | +2.5% | 7.0% | |
Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B |
| Cost of Revenue | 2.21B | 2.51B | 2.63B | 2.72B | 2.79B |
| Gross Profit | 1.33B | 1.46B | 1.5B | 1.33B | 1.23B |
| Gross Margin | 37.7% | 36.8% | 36.4% | 32.9% | 30.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 619.92M | 665.1M | 747.86M | 751M | 743.07M |
| Operating Expenses | 744.78M | 811.68M | 885.3M | 1.1B | 717.73M |
| Depreciation & Amortization | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| EBITDA | 820.16M | 986.15M | 1.03B | 581.14M | 410.84M |
| EBITDA Margin | 23.2% | 24.8% | 25.0% | 14.3% | 10.2% |
| Operating Income | 589.86M | 650.98M | 617.26M | 227.35M | 507.84M |
| Operating Margin | 16.7% | 16.4% | 14.9% | 5.6% | 12.6% |
| Interest Income | 652K | 780K | 5.2M | 8.58M | 4.94M |
| Interest Expense | 73.91M | 59.29M | 136.71M | 126.29M | 107.03M |
| Other Income / Expenses | (109.15M) | (27.99M) | (35.98M) | (134.23M) | (607.34M) |
| Income Before Tax | 480.71M | 622.99M | 581.28M | 93.11M | (99.5M) |
| Pre-Tax Margin | 13.6% | 15.7% | 14.1% | 2.3% | -2.5% |
| Income Tax Expense | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M |
| Net Income | 390.98M | 486.23M | 474.62M | 10.3M | (144.34M) |
| Net Margin | 11.0% | 12.2% | 11.5% | 0.3% | -3.6% |
| EPS (Basic) | 7.77 | 9.57 | 9.27 | 0.20 | (2.91) |
| EPS (Diluted) | 7.60 | 9.48 | 9.22 | 0.20 | (2.91) |
| Weighted Avg Shares | 50.29M | 50.81M | 51.23M | 51.38M | 49.56M |
| Weighted Avg Shares (Diluted) | 51.43M | 51.3M | 51.45M | 51.63M | 49.56M |
Charles River Laboratories International, Inc.
NYSE:CRL
Intrinsic Alpha fair value
Locked
Current Price
$333.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.